Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Bayforest Capital Ltd lessened its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 51.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,723 shares of the company’s stock after selling 3,875 shares during the quarter. Bayforest Capital Ltd’s holdings in Teva Pharmaceutical Industries were worth $57,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Teva Pharmaceutical Industries by 5.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,537,324 shares of the company’s stock valued at $54,369,000 after acquiring an additional 196,261 shares during the last quarter. Zimmer Partners LP bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $11,093,000. Axiom Investors LLC DE bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $33,411,000. Clearline Capital LP bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $7,439,000. Finally, NWI Management LP grew its position in shares of Teva Pharmaceutical Industries by 130.6% during the 1st quarter. NWI Management LP now owns 1,660,000 shares of the company’s stock worth $25,514,000 after buying an additional 940,000 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.4%

Shares of NYSE TEVA opened at $19.96 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The stock has a market capitalization of $22.89 billion, a P/E ratio of -124.75, a price-to-earnings-growth ratio of 1.16 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The business has a fifty day moving average price of $17.31 and a 200 day moving average price of $16.50.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion during the quarter, compared to analysts’ expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm’s quarterly revenue was up .3% on a year-over-year basis. During the same period in the prior year, the business posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares of the company’s stock, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on TEVA shares. UBS Group dropped their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a “buy” rating and a $24.00 price target on the stock. Truist Financial started coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a “buy” rating and a $25.00 price target on the stock. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.